Description: ANI Pharmaceuticals, Inc. develops, manufactures, and markets prescription and over-the-counter pharmaceuticals. It offers liquid, powder, oral solid dose, and cough/cold products; and antacids, laxatives, and other stomach remedies. The company also provides hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture, and metoclopramide tablets. In addition, ANI Pharmaceuticals offers contract manufacturing services for other pharmaceutical companies. It offers its products through wholesalers, smaller regional distributors and chains, and pharmacy and retail outlets in the United States. ANI Pharmaceuticals, Inc. was formerly known as ASHCO. The company was founded in 2001 and is based in Baudette, Minnesota. It has manufacturing facilities in Gulfport, Mississippi; and Baudette, Minnesota. ANI Pharmaceuticals, Inc. is a former subsidiary of Bactolac Pharmaceutical Inc.
Home Page: www.anipharmaceuticals.com
ANIP Technical Analysis
210 Main Street West
Baudette,
MN
56623
United States
Phone:
218 634 3500
Officers
| Name | Title |
|---|---|
| Mr. Nikhil Lalwani | Pres, CEO & Director |
| Mr. Stephen P. Carey | CFO, Sr. VP of Fin. & Corp. Sec. |
| Mr. James G. Marken | Sr. VP of Operations & Product Devel. |
| Mr. Christopher K. Mutz | Head of Rare Disease |
| Mr. Ori Gutwerg | Sr. VP of Generics |
| Mr. Muthusamy Shanmugam MS R.Ph. | Head of R&D, COO of Novitium Operations & Director |
| Ms. Meredith W. Cook | Sr. VP, Gen. Counsel & Corp. Sec. |
| Mr. Chad Gassert | Sr. VP of Corp. Devel. & Strategy |
| Ms. Krista L. Davis | Chief HR Officer |
| Ms. Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 11.8624 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2109 |
| Price-to-Sales TTM: | 2.4194 |
| IPO Date: | 2000-05-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 601 |